Prolonged-release Viramune gains EU approval for HIV
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's once-daily Viramune (nevirapine) prolonged-release tablet has been approved for use in EU in combination with other antiretroviral medications for the treatment of HIV-1 infection.